

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INSYS THERAPEUTICS, INC., *et al.*,

Liquidating Debtors.¹

Chapter 11

Case No. 19-11292 (JTD)

(Jointly Administered)

Hearing Date:

December 17, 2025 at 9:15 a.m. (ET)

Objection Deadline:

December 10, 2025 at 4:00 p.m. (ET)

**MOTION OF THE TRUSTEE OF THE INSYS LIQUIDATION TRUST FOR
ENTRY OF FINAL DECREE CLOSING CERTAIN OF THE CHAPTER 11
CASES; DIRECTING THE USE OF AN AMENDED CAPTION; AND
GRANTING RELATED RELIEF**

William Henrich, in his capacity as liquidating trustee (the “Trustee”) of the Insys Liquidation Trust (the “Trust”), as successor in interest to the above-captioned debtors and debtors in possession (collectively, the “Debtors”), hereby moves (this “Motion”), pursuant to §§ 105(a), 342(c), 350(a) of chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”), Rules 1005, 2002(n), and 3022 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), and Rule 3022-1(a) of the Local Rules of the United States Bankruptcy Court for the District of Delaware (the “Local Rules”), for entry of a final decree, substantially in the form annexed hereto as **Exhibit A** (the “Proposed Final Decree”), (a) closing the chapter 11 cases of all of the Debtors other than Insys Therapeutics, Inc. (“Insys Therapeutics”), (b) providing that, to the extent necessary, any further proceedings in this Court with respect to unresolved claims and other remaining matters that may potentially impact the estates of the Subsidiary Cases (as defined

¹ The Liquidating Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, are: Insys Therapeutics, Inc. (7886); IC Operations, LLC (9659); Insys Development Company, Inc. (3020); Insys Manufacturing, LLC (0789); Insys Pharma, Inc. (9410); IPSC, LLC (6577); and IPT 355, LLC (0155).

below) shall be administered in the Lead Case (as defined below), (c) directing the use of an amended caption upon entry of the Proposed Final Decree, and (d) granting limited relief from Local Rule 3022-1(c). In support of this Motion, the Trustee respectfully represents as follows:

Preliminary Statement

1. By this Motion, the Trustee seeks to close all of the chapter 11 cases listed on Exhibit B hereto (collectively, the “Subsidiary Cases”) and leave open Insys Therapeutics case (the “Lead Case”) to continue the administration of the Trust. Immediately closing the Subsidiary Cases will alleviate the Trustee from both (a) the administrative burden of professional costs and internal resources in maintaining the Subsidiary Cases, and (b) the continued payment of U.S. Trustee fees that the Trust is required to pay every quarter for each of the seven (7) Debtors.

Jurisdiction

2. The Court has jurisdiction to consider this Motion pursuant to 28 U.S.C. §§ 157 and 1334, the *Amended Standing Order of Reference* dated February 29, 2012 (Sleet, C.J.), and Section X(14) of the Plan (defined below), pursuant to which the Court retained jurisdiction to, among other things, enter a final decree closing the Debtors’ Chapter 11 cases. This is a core proceeding pursuant to 28 U.S.C. § 157(b). Venue is proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409.

Background

3. On June 10, 2019 (the “Petition Date”), the Debtors each filed with this Court a voluntary petition for relief under chapter 11 of the Bankruptcy Code. The Debtors’ bankruptcy cases are jointly administered under Case No. 19-11292 (collectively, the “Cases”).

4. On January 16, 2020, this Court entered an order [Docket No. 1115] (the “Confirmation Order”) confirming the *Second Amended Joint Chapter 11 Plan of Liquidation of*

Insys Therapeutics, Inc. and Its Affiliated Debtors (the “Plan”) in the Chapter 11 Cases. On February 18, 2020 (the “Effective Date”), the Plan became effective in accordance with its terms and, in accordance with the Plan, Confirmation Order and that certain *Trust Agreement for Insys Liquidation Trust* (the “Trust Agreement”), certain assets² of the Debtors existing as of such date were transferred to and became vested in the Trust, and William Henrich was appointed the Trustee of the Trust.

Substantive Consolidation under the Plan

5. The Plan provides for, among other things, the substantive consolidation (the “Substantive Consolidation”) of the Debtors’ assets and liabilities for the purposes of implementing and making distributions and liquidating all Trust assets. Indeed, as of the Effective Date (a) all assets and liabilities of the Debtors were deemed merged, (b) all guarantees by one Debtor of the obligations of any other Debtor were eliminated, and all guarantees executed by multiple Debtors of the obligations of any other entity were deemed consolidated into a single obligation, so that any claim against any Debtor and any guarantee thereof executed by any other Debtor and any joint or several liability of any of the Debtors were deemed to be one obligation of the Debtors, and (c) any claim filed against any Debtor is deemed filed against all Debtors and constitutes one claim against, and a single obligation of, the Debtors.

Post-Confirmation Reports and Fees

6. Notwithstanding the Substantive Consolidation, the Plan and Confirmation Order provide that fees payable pursuant to 28 U.S.C. § 1930 and 31 U.S.C. § 3717 (“US Trustee Fees”) for each of the Debtors’ estates after the Effective Date, will be paid from the Trust by the Trustee

² These assets include all assets of the Debtors other than (i) the VRT Operating Reserve, (ii) the Products Liability Insurance Rights, and (iii) any Interests held by Liquidating Debtors in other Liquidating Debtors, as defined in the Plan.

until the closing of the applicable Cases pursuant to section 350(a) of the Bankruptcy Code. *See* Plan at Section 12.6; Confirmation Order at ¶ 12.

7. As of the date of this Motion, all requisite post-confirmation reports have been filed through the third quarter of 2025 and all U.S. Trustee Fees in these Cases have been paid timely. The Trustee seeks to close the Subsidiary Cases to avoid incurring further unnecessary US Trustee Fees. If the relief requested herein is granted, the Trust anticipates filing one last post-confirmation report in each of the Subsidiary Cases (as well as one for the Lead Case) for the fourth quarter of 2025 and making a payment to the U.S. Trustee of any appropriate US Trustee Fees required for the all the Cases at that time.

Relief Requested

8. By this Motion, the Trustee requests entry of the Proposed Final Decree, pursuant to §§ 105(a), 342(c)(1) and 350(a) of the Bankruptcy Code, Bankruptcy Rules 1002, 2002(n) and 3022 and Local Rule 3022-1(a), (a) closing all of the Subsidiary Cases and leaving open the Lead Case until the Trust is fully administered, (b) providing that, to the extent necessary, further proceedings in this Court with respect to unresolved claims asserted against the Debtors in the Subsidiary Cases and other matters that may potentially impact the estates of the Debtors in the Subsidiary Cases be administered in the Lead Case, (c) directing the use of an amended caption upon the entry of the Proposed Final Decree approving this Motion, and (d) granting limited relief from Local Rule 3022-1. After the Subsidiary Cases are closed, all motions, notices, and other pleadings relating to any of the Debtors or the Trust shall continue to be filed in the Lead Case.

Closure of Specified Cases

9. Section 350(a) of the Bankruptcy Code provides that “[a]fter an estate is fully administered and the court has discharged the trustee, the court shall close the case.” 11 U.S.C. §

350(a). Bankruptcy Rule 3022 implements § 350 of the Bankruptcy Code and provides that “[a]fter an estate is fully administered in a chapter 11 reorganization case, the court, on its own motion or on motion of a party in interest, shall enter a final decree closing the case.” Fed. R. Bankr. P. 3022.

10. The term “fully administered” is not defined in the Bankruptcy Code or the Bankruptcy Rules, but the Advisory Committee Note to Bankruptcy Rule 3022 delineates the following nonexclusive factors to be considered in determining whether an estate has been fully administered:

- a. whether the order confirming the plan has become final,
- b. whether deposits required by the plan have been distributed,
- c. whether the property proposed by the plan to be transferred has been transferred,
- d. whether the debtor or the successor of the debtor under the plan has assumed the business or the management of the property dealt with by the plan,
- e. whether payments under the plan have commenced, and
- f. whether all motions, contested matters, and adversary proceedings have been finally resolved.

Fed. R. Bankr. P. 3022 Advisory Committee’s Note. The Advisory Committee Note further indicates that entry of a final decree “should not be delayed solely because the payments required by the plan have not been completed,” and the Court “should not keep the case open only because of the possibility that the court’s jurisdiction may be invoked in the future.” *Id.* Additionally, “a final decree closing the case after the estate is fully administered does not deprive the court of jurisdiction to enforce or interpret its own orders and does not prevent the court from reopening the case for cause pursuant to [section] 350(b) of the [Bankruptcy] Code.” *Id.* Indeed, Bankruptcy Rule 3022 was amended in order to

set forth a flexible Rule to permit the court to determine that an estate is fully administered and should be closed even though payments or other activities involving the debtor and its creditors might continue. . . . As is evident by the Committee note, the Advisory Committee interprets “fully administered” *very loosely and encourages courts to use substantially more*

discretion in deciding whether to close a [c]hapter 11 case th[a]n Code § 350 and the Rule literally read.

In re Gould, 437 B.R. 34, 37-38 (Bankr. D. Conn. 2010) (quoting Fed. R. Bankr. P. 3022 ed. cmt.) (emphasis added).

11. Courts have typically applied the six factors listed in the Rule 3022 Advisory Committee's Note to determine whether an estate has been fully administered so as to determine if closing a case is timely. *See, e.g., Ericson v. IDC Servs., Inc. (In re IDC Servs., Inc.)*, No. 97 CIV. 3081(TPG), Ch. 11 Case No. 93 B 45922(SMB), 1998 WL 547085, at *3 (S.D.N.Y. Aug. 28, 1998) (“[T]he approach that looks to the Advisory Note provides a more complete and flexible standard for determining when to close a chapter 11 case, and is therefore preferable.”). However, courts have adopted the view that “these factors are but a guide in determining whether a case has been fully administered, and not all factors need to be present before the case is closed.” *In re SLI, Inc.*, Case No. 02-12608, 2005 WL 1668396, at *2 (Bankr. D. Del. 2005); *see also In re Gould*, 437 B.R. at 37–38 (“As is evident by the Committee note, the Advisory Committee interprets ‘fully administered’ very loosely and encourages courts to use substantially more discretion in deciding whether to close a [c]hapter 11 case th[a]n Code § 350 and the Rule literally read.”); *In re Kliegel Bros. Universal Elec. Stage Lighting Co., Inc.*, 238 B.R. 531, 543 (Bankr. E.D.N.Y. 1999) (“The factors set forth in the Note are plainly an aid or checklist”); *In re Mold Makers, Inc.*, 124 B.R. 766, 768 (Bankr. N.D. Ill. 1990) (“[A]ll of the factors in the Committee Note need not be present before the Court will enter a final decree. Instead, the Committee Note and the factors therein merely serve as a guide in assisting the Court in its decision to close a case.”); *In re Federated Department Stores, Inc.*, 43 Fed. Appx. 820, 822 (6th Cir. 2002) (“A court should review each request for entry of a final decree on a case-by-case basis and analyze the factors set forth in Rule 3022, along with any other relevant factors, in determining whether an estate has

been fully administered.”); *In re Jay Bee Enters., Inc.*, 207 B.R. 536, 538 (Bankr. E.D. Ky. 1997) (“Rule 3022 allows the court flexibility. It does not require that a chapter 11 case be kept open until all awarded fees and allowed claims have been paid in accordance with the confirmed plan or until the statutory fees . . . have been paid.”); *Walnut Assocs. V. Sidel*, 164 B.R. 487, 493 (E.D. Pa. 1994) (“[A]ll of the factors in the Committee Note need not be present before the Court will enter a final decree.”).

12. Here, the Plan was deemed to be substantially consummated on the Effective Date pursuant to §§ 1101 and 1127 of the Bankruptcy Code. In addition, given the Substantive Consolidation, all actions that must be taken before this Court can be addressed in the Lead Case. The Subsidiary Cases have, therefore, been “fully administered” within the meaning of § 350 of the Bankruptcy Code, or have been substantially administered and can be fully administered by the Lead Case. Among other things:

- a. the Confirmation Order has become final and nonappealable;
- b. the Debtors are no longer conducting business;
- c. the Trust contemplated by the Plan has been established;
- d. all property proposed to be transferred pursuant to the Plan has been transferred to the Trust;
- e. all of the distributions provided for under the Plan have been made or will be made by the Trustee in accordance with the terms of the Plan and Trust Agreement; and
- f. notwithstanding the closing of the Subsidiary Cases, pursuant to the Plan, any disputed claims against or retained causes of action of the applicable Debtors may be compromised, settled, otherwise resolved by the Trustee in the Lead Case.

13. The foregoing factors support closing the Subsidiary Cases. Numerous courts in this and other districts have closed chapter 11 cases notwithstanding unresolved claims to avoid the incurrence of unnecessary US Trustee Fees. *See, e.g., In re M & G USA Corporation, et al.*, Case No. 17-12307 (BLS) (Bankr. D. Del. June 3, 2020) (closing all chapter 11 cases other than lead case, notwithstanding ongoing claims reconciliation); *In re Cenveo, Inc.*, Case No. 18-22178

(RDD) (Bankr. S.D.N.Y. Nov. 21, 2018) (ECF No. 849); *In re 21st Century Oncology Holdings, Inc.*, Case No. 17-22770 (RDD) (Bankr. S.D.N.Y. Mar. 23, 2018) (ECF No. 1038) (same); *In re Gibson Brands, Inc.*, Case No. 18-11025 (CSS) (Bankr. D. Del. Dec. 20, 2018) (ECF No. 1101) (same); *In re Claire's Stores, Inc.*, Case No. 18-10584 (MFW) (Bankr. D. Del. Nov. 27, 2018) (ECF No. 1165) (same); *In re ExGen Texas Power, LLC*, No. 17-12377 (BLS) (Bankr. D. Del. Aug. 21, 2018) (ECF No. 405) (same); *In re Energy Future Holdings Corp.*, No. 14-10979 (CSS) (Bankr. D. Del. Nov. 3, 2017) (ECF No. 12172) (same).

14. No party in interest will be prejudiced if the Subsidiary Cases are closed because the Lead Case will provide an avenue for resolving any claims that relate to the Subsidiary Cases, regardless of which Debtor such claims were filed against, as well as provide an avenue for the Trust (and the Trustee) to prosecute claims and defenses in connection with the retained causes of action. Indeed, closing the Subsidiary Cases is solely administrative. The Court will retain jurisdiction over any issues relating to the Subsidiary Cases, including the resolution of claims, any pending contested matters, and any adversary proceedings or other litigation. Accordingly, closing the Subsidiary Cases will not have any substantive impact on creditors in the Subsidiary Cases.

15. Closing the Subsidiary Cases is supported by the Plan since it provides for the Substantive Consolidation. Indeed, any claim against any Debtor is deemed to be one obligation of the Debtors and constitutes one claim against, and a single obligation of, the Debtors. Accordingly, closing the Subsidiary Cases will not frustrate or compromise the Trust's reconciliation of claims or claimants' distributions in connection therewith. *See In re Pulp Finish 1 Company*, Case No. 12-13774 (SMB), 2014 WL 201482, at *11 (Bankr. S.D.N.Y. Jan. 16, 2014) (The creditor "would not be prejudiced because the [plan] consolidated the Debtors for purposes

of . . . making distributions, and all of the assets and liabilities were deemed to be those of a single, consolidated entity.”); *In re Chaparral Energy, Inc.*, Case No. 16-11144 (LSS) (Bankr. D. Del. March 19, 2018) (ECF No. 1288) (closing subsidiary cases where holders of allowed general unsecured claimants would receive equal treatment from recovery pool regardless of which specific debtor their claim were filed against); *In re Gibson Brands, Inc.*, No. 18-11025 (CSS) (Bankr. D. Del. Dec. 20, 2018) (ECF No. 1101) (same).

Use of Amended Caption

16. The Proposed Final Decree directs the use of an amended caption in the Lead Case, as follows:

	:	
In re:	:	Chapter 11
	:	
INSYS THERAPEUTICS, INC.,	:	Case No. 19-11292 (BLS)
	:	
Liquidating Debtor.	:	
	:	

17. The Court has the authority to direct the use of an amended caption under §§ 105(a) and 342(c)(1) of the Bankruptcy Code, as well as Bankruptcy Rules 1005 and 2002(n). Section 342(c) of the Bankruptcy Code requires, in relevant part, that notices “required to be given by the debtor to a creditor . . . shall contain the name, address, and last 4 digits of the taxpayer identification number of the debtor.” 11 U.S.C. § 342(c)(1). Similarly, Bankruptcy Rule 1005 requires that a proper caption include the name of the debtor and last 4 digits of the taxpayer identification number of the debtor. Section 105(a) provides this Court with the authority to issue orders that are necessary to carry out the provisions of the Bankruptcy Code. 11 U.S.C. § 105(a). Bankruptcy Rule 2002(n) requires that the caption of every notice include the information required to be in the notice by section 342(c) of the Bankruptcy Code and Bankruptcy Rule 1005. Similarly, Local

Rule 9004-1 provides that “[d]ocuments submitted for filing shall contain in the caption the name of the debtor, the case number, the initials of the Judge to whom the case has been assigned, the docket number assigned to the case and, if applicable, the adversary proceeding number.”

18. The use of the amended caption proposed herein is necessary to reflect the closure of the Subsidiary Cases. Specifically, the proposed caption will accurately reflect that, following entry of the relief requested herein, that Insys Therapeutics is the only case open and pending. Accordingly, the Trustee submits that it is necessary and appropriate to modify the caption of the Cases as set forth above.

Administration of Unsolved Matters

19. Section 105(a) of the Bankruptcy Code provides that “[t]he court may issue any order, process, or judgment that is necessary or appropriate to carry out the provisions of [the Bankruptcy Code].” 11 U.S.C. § 105(a). Closing the Subsidiary Cases and administering any unresolved matters with respect to such cases in the Lead Case is an appropriate use of the Court’s equitable powers under section 105(a) of the Bankruptcy Code.

20. A principal purpose behind this Motion – other than the reduction of administrative burdens on this Court and the Clerk of the Court – is to limit the incurrence of quarterly fees payable to the Office of the United States Trustee. At present, the Subsidiary Cases accrue \$1,500.00 per quarter in fees. This ongoing financial burden on the Trust provides little by way of corresponding benefit to the Trust beneficiaries or to any remaining creditors. The Subsidiary Cases sought to be closed by this Motion have little to no activity in them each quarter, nor are they expected to have any substantial activity in the future.

21. It is unnecessary to keep the Subsidiary Cases open on account of the relatively few unresolved matters remaining in the Subsidiary Cases, particularly when the Court can continue

to address such matters under the umbrella of the Lead Case. Indeed, as long the Lead Case remains open, closure of the Subsidiary Cases will not affect the resolution of the outstanding proofs of claim asserted against, or other matters involving, the applicable Debtors. Rather, upon entry of the relief requested herein, any remaining matters that might potentially impact the estates of the Debtors in the Subsidiary Cases can either be addressed adequately in the Lead Case or, if necessary, with the reopening of relevant Subsidiary Case.

22. The form of Proposed Final Decree attached hereto provides for the Court to retain jurisdiction over the Subsidiary Cases in the event that the Trustee or any other party in interest seeks to reopen any of the Subsidiary Cases for cause. The retention of jurisdiction by the Court for such purpose is appropriate, and consistent with the terms of the Confirmation Order. See 28 U.S.C. § 1334(b) (granting courts “related to” jurisdiction); *Pacor, Inc. v. Higgins*, 743 F.2d 984 (3d Cir. 1985) (providing definition of “related to” for jurisdictional purposes); see also Section X(14) of the Plan. Therefore, granting the relief requested herein would not foreclose the possibility of reopening the Specified Cases should the need arise.

Final Report

23. The Trustee has paid approximately a total of \$28,500 in US Trustee fees for the Subsidiary Cases. Unless and until the Court enters a final decree closing the Subsidiary Cases, US Trustee fees must continue to be paid. Allowing the Subsidiary Cases to be closed will preserve value for the beneficiaries of the Trust by eliminating a substantial expense that continues to accrue while the Subsidiary Cases unnecessarily remain open.

24. Pursuant to Local Rule 3022-1, all fees required to date pursuant to 28 U.S.C. § 1930 have been paid, or will be paid, by the Trustee relative to the Subsidiary Cases. The Trustee respectfully requests a waiver of the requirement under Local Rule 3022-1(a)(ii) to file a final

report with respect to the Subsidiary Cases prior to the hearing on this Motion. The Trustee instead proposes to file a consolidated final report with respect to all of the Debtors in connection with a motion seeking to close the Lead Case.

Notice

25. Notice of this Motion has been provided to the Office of the United States Trustee for the District of Delaware and parties entitled to receive notice pursuant to Bankruptcy Rule 2002. The Trustee submits that no other or further notice need be given.

Conclusion

WHEREFORE the Trustee respectfully requests entry of the Proposed Final Decree granting the relief requested herein and such other and further relief as is just.

Dated: November 26, 2025

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Matthew O. Talmo

Derek C. Abbott (No. 3376)
Matthew O. Talmo (No. 6333)
1201 N. Market Street, 16th Floor
P.O. Box 1347
Wilmington, DE 19899-1347
Telephone: (302) 658-9200
Facsimile: (302) 658-3989
dabbott@morrisnichols.com
mtalmo@morrisnichols.com

-and-

**HALPERIN BATTAGLIA BENZIJA,
LLP**

Alan D. Halperin
Scott A. Ziluck
Ligee Gu
40 Wall Street, 37th Floor
New York, NY 10005
Telephone: (212) 765-9100
Facsimile: (212) 765-0964
ahalperin@halperinlaw.com
sziluck@halperinlaw.com
lgu@halperinlaw.com

*Counsel to the Trustee of the Insys
Liquidation Trust*

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INSYS THERAPEUTICS, INC., *et al.*,

Liquidating Debtors.¹

Chapter 11

Case No. 19-11292 (BLS)

(Jointly Administered)

Hearing Date:

December 17, 2025, at 9:15 a.m. (ET)

Objection Deadline:

December 10, 2025, at 4:00 p.m. (ET)

**NOTICE OF MOTION OF THE TRUSTEE OF THE INSYS LIQUIDATION TRUST
FOR ENTRY OF FINAL DECREE CLOSING CERTAIN OF THE CHAPTER 11
CASES; DIRECTING THE USE OF AN AMENDED CAPTION; AND GRANTING
RELATED RELIEF**

PLEASE TAKE NOTICE that today, William Henrich, in his capacity as liquidating trustee (the “Trustee”) of the Insys Liquidation Trust (the “Trust”) filed the *Motion of the Trustee of the Insys Liquidation Trust for Entry of Final Decree Closing Certain of the Chapter 11 Cases; Directing the Use of an Amended Caption; and Granting Related Relief* (the “Motion”).

PLEASE TAKE FURTHER NOTICE that objections, if any, to the Motion must be (a) in writing and served on or before **December 10, 2025, at 4:00 p.m. (ET)** (the “Objection Deadline”); (b) filed with the Clerk of the Bankruptcy Court, 824 N. Market Street, 3rd Floor, Wilmington, Delaware 19801; and (c) served so as to be received on or before the Objection Deadline by the undersigned counsel.

PLEASE TAKE FURTHER NOTICE THAT only objections made in writing and timely filed and received, in accordance with the procedures above, will be considered by the Bankruptcy Court at such hearing.

PLEASE TAKE FURTHER NOTICE THAT A HEARING ON THE MOTION WILL BE HELD ON **DECEMBER 17, 2025, AT 9:15 A.M. (ET)** BEFORE THE HONORABLE BRENDAN L. SHANNON OF THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE.

¹ The Liquidating Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, are: Insys Therapeutics, Inc. (7886); IC Operations, LLC (9659), Insys Development Company, Inc. (3020); Insys Manufacturing, LLC (0789); Insys Pharma, Inc. (9410); IPSC, LLC (6577); and IPT 355, LLC (0155).

IF YOU FAIL TO RESPOND IN ACCORDANCE WITH THIS NOTICE, THE COURT MAY GRANT THE RELIEF REQUESTED IN THE MOTION WITHOUT FURTHER NOTICE OR HEARING.

Dated: November 26, 2025

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Matthew O. Talmo

Derek C. Abbott (No. 3376)
Matthew O. Talmo (No. 6333)
1201 N. Market Street, 16th Floor
P.O. Box 1347
Wilmington, DE 19899-1347
Telephone: (302) 658-9200
Facsimile: (302) 658-3989
dabbott@morrisnichols.com
mtalmo@morrisnichols.com

-and-

**HALPERIN BATTAGLIA BENZIJA,
LLP**

Alan D. Halperin
Scott A. Ziluck
Ligee Gu
40 Wall Street, 37th Floor
New York, NY 10005
Telephone: (212) 765-9100
Facsimile: (212) 765-0964
ahalperin@halperinlaw.com
sziluck@halperinlaw.com
lgu@halperinlaw.com

*Counsel to the Trustee of the Insys
Liquidation Trust*

Exhibit A

Form of Proposed Final Decree

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

INSYS THERAPEUTICS, INC., *et al.*,

Liquidating Debtors.¹

Chapter 11

Case No. 19-11292 (JTD)

(Jointly Administered)

Re: D.I. ____

**FINAL DECREE CLOSING SUBSIDIARY CASES
AND GRANTING RELATED RELIEF**

Upon the motion (the “Motion”),² of William Henrich, in his capacity as liquidating trustee (the “Trustee”) of the Insys Liquidation Trust (the “Trust”), pursuant to §§ 105(a), 342(c), and 350(a) of chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”), Rules 1005, 2002(n), and 3022 of the Federal Rules of Bankruptcy Procedure (the “Bankruptcy Rules”), and Rule 3022-1(a) of the Local Rules of the Bankruptcy Court for District of Delaware (the “Local Rules”), for a final decree closing the Subsidiary Cases and leaving open the Lead Case, all as more fully described in the Motion; and the Court having jurisdiction to consider the Motion and the relief requested therein in accordance with 28 U.S.C. §§ 157 and 1334, the *Amended Standing Order of Reference* dated February 29, 2012, and Section X(14) of the Plan, pursuant to which the Court retained jurisdiction to, among other things, enter a final decree closing the Debtors’ chapter 11 cases; and consideration of the Motion and the relief requested therein being a core proceeding pursuant to 28 U.S.C. § 157(b); and venue being proper before this Court pursuant to 28 U.S.C.

¹ The Liquidating Debtors in these cases, along with the last four digits of each Debtor’s federal tax identification number, are: Insys Therapeutics, Inc. (7886); IC Operations, LLC (9659), Insys Development Company, Inc. (3020); Insys Manufacturing, LLC (0789); Insys Pharma, Inc. (9410); IPSC, LLC (6577); and IPT 355, LLC (0155).

² Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to such terms in the Motion.

§§ 1408 and 1409; and notice of the Motion having been given as provided in the Motion, and such notice having been adequate and appropriate under the circumstances, and it appearing that no other or further notice need be provided; and there being no objection to the Motion; and the Court having found and determined that the relief sought in the Motion is in the best interests of the Debtors, their estates, the Trust, its beneficiaries, creditors, and all parties in interest, and that the legal and factual bases set forth in the Motion establish just cause for the relief granted herein; and after due deliberation and sufficient cause appearing therefor,

IT IS HEREBY ORDERED THAT

1. The Motion is granted as provided herein.
2. Pursuant to §§ 105(a) and 350(a) of the Bankruptcy Code, Bankruptcy Rule 3022, and Local Rule 3022-1(a), the following chapter 11 cases are hereby closed and a final decree (the “Final Decree”) is granted:

IC Operations LLC	19-11293
Insys Development Company, Inc.	19-11294
Insys Manufacturing, LLC	19-11295
Insys Pharma, Inc.	19-11296
IPSC, LLC	19-11297
IPT 355, LLC	19-11298
IC Operations LLC	19-11293
Insys Development Company, Inc.	19-11294

3. The chapter 11 case of Insys Therapeutics, Inc., Case No. 19-11292 (BLS) (the “Lead Case”), shall remain open pending further order of this Court and, from and after the date of entry of this Final Decree, all motions, notices, and other pleadings relating to any of the Debtors or Trust shall be filed in the Lead Case.

4. The Clerk of this Court shall enter this Final Decree individually on each of the dockets of the Subsidiary Cases and each of the dockets of the Subsidiary Cases shall be marked as “Closed.”

5. An entry shall be made on the docket of each of the Debtors' cases, other than that of the Subsidiary Cases, that is substantially similar to the following:

An order has been entered in accordance with Rule 3022-1 of the Local Rules of the United States Bankruptcy Court for the District of Delaware closing the chapter 11 cases of: IC Operations LLC, Insys Development Company, Inc., Insys Manufacturing, LLC, Insys Pharma, Inc., IPSC, LLC, IPT 355, LLC, IC Operations LLC, and Insys Development Company, Inc. All further pleadings and other papers shall be filed in and all further docket entries shall be made in the chapter 11 case of Insys Therapeutics, Inc., Case No. 19-11292 (JTD).

6. Notwithstanding the possible application of Bankruptcy Rules 7062, 9014 or otherwise, the terms and conditions of this Final Decree shall be immediately effective and enforceable upon its entry.

7. After the Subsidiary Cases are closed, the Trustee shall not be required to file post-confirmation reports in those cases and no U.S. Trustee fees shall be assessed unless those cases are reopened.

8. The Trust shall continue to pay U.S. Trustee Fees solely with respect to disbursements made in the Lead Case.

9. The Trust shall, within 30 days after entry of this Final Decree, (a) pay all fees due and payable pursuant to 28 U.S.C. § 1930(a)(6). Entry of this Final Decree is without prejudice to the rights of the U.S. Trustee to reopen those Chapter 11 Cases closed hereby to seek appropriate relief in the event of an unresolved dispute over the payment of fees pursuant to 28 U.S.C. § 1930(a)(6) or the post-confirmation reports.

10. The Trust shall provide the U.S. Trustee all quarterly reports not already filed with respect to the Chapter 11 Cases of the Subsidiary Debtors, including reports for any partial quarter within 21 days after entry of this Order.

11. Entry of this Final Decree (a) is without prejudice to the rights of the Trust (and the Trustee) to commence, prosecute, and/or resolve any claim or cause of action against any party or object to or resolve claims filed against any of the Debtors as provided in the Plan, (b) is without prejudice to the rights, claims and defenses of any creditor, defendant or any other party in interest with respect to any claim or cause of action, and (c) shall have no effect whatsoever on any contested matter, adversary proceeding, or other matters pending before this Court, or which may be brought before this Court by any party, in each case, subject to the terms of the Plan and the Confirmation Order.

12. Notwithstanding entry of this Final Decree, as provided in the Plan, the Trustee shall be entitled to prosecute claims and defenses, make distributions, and attend to other wind-down affairs on behalf of the Trust and otherwise administer the Trust as if the estates of the Debtors in the Subsidiary Cases continued to exist solely for these purposes.

13. Notwithstanding the entry of this Final Decree or § 550(f) of the Bankruptcy Code, the closing of the Subsidiary Cases shall not affect the rights of the Trust or the Trustee to commence or maintain any action or proceeding, including without limitation actions to recover from any transferee or any subsequent transferee, in each case, subject to the terms of and as provided in the Plan and the Confirmation Order.

14. Following entry of this Final Decree, the caption for the Lead Case shall read as follows:

In re: INSYS THERAPEUTICS, INC., Liquidating Debtor.	: : : : : : : : :	Chapter 11 Case No. 19-11292 (BLS)
--	---	---

15. Notwithstanding entry of this Final Decree, the requirements of Local Rules 2002-1(e)(ix) and 3022-1(a)(ii) are waived with respect to the Subsidiary Cases, provided that the Trustee shall file a final report in accordance with Local Rule 3022-1(a)(ii) with respect to the consolidated Debtors as soon as reasonably practicable upon entry of an order closing the Lead Case.

16. The Trustee is authorized to take all actions necessary to effectuate the relief granted in this Final Decree.

17. Entry of this Final Decree and the closing of the Subsidiary Cases is for administrative purposes only and shall not create or prejudice any right, claim, defense or cause of action by or of a creditor, defendant or other party in interest in any other regard.

18. Entry of this Final Decree is without prejudice to the rights of any party in interest to seek to reopen any of the Subsidiary Cases for cause shown.

19. This Court shall retain jurisdiction to hear and determine all matters arising from or related to the implementation, interpretation and/or enforcement of this Final Decree.

Exhibit B

Subsidiary Debtor	Case Number
IC Operations LLC	19-11293
Insys Development Company, Inc.	19-11294
Insys Manufacturing, LLC	19-11295
Insys Pharma, Inc.	19-11296
IPSC, LLC	19-11297
IPT 355, LLC	19-11298